Skip to content

Predictive value of IL-17A, S100A8/9 and IGFBP5 in patients with initial acute myocardial infarction

Predictive value of IL-17A, S100A8/9 and IGFBP5 in patients with initial acute myocardial infarction

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300069463
Enrollment
Unknown
Registered
2023-03-17
Start date
2021-02-01
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction

Interventions

Healthy control group:none

Sponsors

The First Affiliated Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 75 Years

Inclusion criteria

Inclusion criteria: AMI patients: 1. Aged 20-75 years, regardless of gender; 2. Chest pain symptoms of myocardial ischemia; 3. Significant new ST-segment T-wave changes in the ECG and definitive diagnosis of non-ST elevation MI or ST elevation MI; 4. The reference value of cardiac troponin is at least above the upper 99th percentile; 5. Clear occlusion during acute PCI and angiography; 6. The first coronary artery reperfusion was successfully performed during PCI; Healthy controls(non-AMI): 1. Aged 20-75 years, regardless of gender; 2. Normal range electrocardiogram; 3. No known heart disease; 4. Computed tomography angiography results were classified as negative for coronary artery disease.

Exclusion criteria

Exclusion criteria: 1. Percutaneous coronary intervention for associated myocardial infarction; 2. Myocardial infarction associated with coronary artery bypass grafting; 3. Recurrent myocardial infarction or reinfarction; 4. Necrotizing myocardial injury caused by transcatheter aortic valve implantation or mitral valve clamp or arrhythmia ablation; 5. Myocardial damage or infarction associated with heart failure; 6. Atrial fibrillation and structural heart disease; 7. Other comorbidities that are not well controlled clinically (cancer, rheumatoid arthritis, liver or kidney disease, hematological disorders, chronic inflammation); 8. Patients with cognitive dysfunction and dementia; 9. Patients who do not want to sign informed consent.

Design outcomes

Primary

MeasureTime frame
IL-17A;S100A8/9;Major adverse cardiovascular events;IGFBP5;

Countries

china

Contacts

Public ContactXinli Li

The First Affiliated Hospital of Nanjing Medical University

zhuqq@njmu.edu.cn+86 25 68303130

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026